Urolithin A for Endurance

Verdict: Weak, disputed evidence for endurance

Urolithin A has not been shown to reliably improve endurance: across four small trials the pre-specified performance endpoints consistently failed, and only softer secondary measures moved. Treat any "boosts endurance" marketing with skepticism.

C 🟠 C Weak Evidence Disputed

🔬Why this grade7-layer evidence engine

The grade is C (weak, disputed) because the human evidence is thin and internally split. Four double-blind RCTs (total n is roughly 216) share the same telltale pattern: the main outcome each trial set out to move did not budge. Peak cycling power was not met in middle-aged adults (PMID 35584623), the 6-minute walk distance was not significant in older adults (PMID 35050355), and a 3000 m time trial did not improve in highly trained runners (PMID 40839339, p=0.116).

What did move were secondary and biomarker measures, pointing in a broadly favorable direction: within-group VO2 and strength gains (PMID 35584623), better muscle endurance (PMID 35050355), lower perceived exertion and reduced muscle-damage markers (PMID 40839339), and more reps to failure in a small resistance-training trial (PMID 39487653). These signals are encouraging but exploratory, and the smallest study (n=20) was low quality with undisclosed funding. At least three of the four trials were funded by the manufacturer, which is why the engine attaches an industry conflict-of-interest flag.

Regulators (FDA, EFSA, Australia's TGA, Health Canada) have addressed only food safety, clearing intake up to about 500 mg/day, and have approved no endurance or performance claim. No clinical authority weighs in either: NIH ODS, Mayo, Cleveland and Harvard are silent, and sports-science bodies (ACSM, IOC, ISSN, AIS) have not placed Urolithin A in any evidence category. That gap, combined with the null primary endpoints, keeps this honestly at weak/disputed.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.50
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Disputed
Confidence
61%
Broadly consistent
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L5 Clinical bodiesAuthoritative stance
0.50
L11 AI re-checkIndependent read
0.50
L2 PubMedPrimary literature
0.60
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.503
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 1 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in middle-aged adults
PMID: 35584623 2022 RCT (double-blind) n = 88
Finding: Primary endpoint (peak power output) NOT met; secondary endpoints showed within-group peak VO2 increase at 1000 mg (p<0.01) and hamstring strength gains at both doses (p=0.027 / p=0.029 vs placebo)
⚠️ Industry-funded
View on PubMed
Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial
PMID: 35050355 2022 RCT (double-blind) n = 66
Finding: Muscle endurance (FDI and tibialis anterior) significantly improved at 2 months (p<0.01); primary 6MWD (UA +60.8m vs placebo +42.5m) and ATP production NOT statistically significant
⚠️ Industry-funded
View on PubMed
Urolithin A Supplementation on Running Performance, Recovery, and Mitochondrial Biomarkers in Highly Trained Male Distance Runners
PMID: 40839339 2025 RCT (double-blind) n = 42
Finding: 3000 m time trial NOT improved (p=0.116); VO2max within-group +5.4% in UA (p=0.009) vs +3.6% placebo (p=0.098); RPE lower (p=0.02); CK damage marker reduced (AUC p<0.0001)
🟢 High quality ⚠️ Industry-funded Effect size: [object Object]
View on PubMed
Assessment of Urolithin A effects on muscle endurance, strength, inflammation, oxidative stress, and protein metabolism in male athletes with resistance training
PMID: 39487653 2024 RCT (double-blind) n = 20
Finding: Repetitions to failure improved vs placebo (p=0.011); MVIC improved vs placebo (p=0.048); CRP lower vs placebo (p=0.032); small sample (n=20) limits generalizability
🟠 Limited quality
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
FDA has no questions source↗
L4b EU EFSA
Neutral
In 2022, the European Food Safety Authority (EFSA) gave a positive opinion on the safety of Urolithin A for use in food supplements for the general adult population. The EFSA report emphasized no adverse effects under the proposed daily dose of up to 500 mg/day. source↗
L4c UK NHS
Not addressed
Application for the approval of Urolithin A as a novel food. Applicant: Amazentis SA. Status: In progress. Current Phase: Risk assessment In progress. [ACNFP 173rd meeting, 24-25 Sept 2025] The applicant proposes urolithin A in conventional foods, cereal bars, protein bars, nutrition bars targeting athletes, yoghurt products, specialised foods for adults only, including meal replacements, nutri… source↗
L4e WHO
Supportive
Urolithin A is a synthetic version of urolithin A of the compound formed endogenously following consumption of ellagic acid and ellagitannins. Urolithin A is manufactured via chemical synthesis involving a chemical reaction between 2-bromo-5-hydroxybenzoic acid and resorcinol in the presence of sodium hydroxide and catalyst of cupric sulfate pentahydrate, followed by protonation of the resultin… source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-endurance-INT-urolithin-a-001 繁體中文版 →